Periodic Reporting for period 1 - PrintMed (Printing personalised medicines on demand)
Okres sprawozdawczy: 2020-11-01 do 2022-12-31
Personalized medicine has become increasingly more prevalent in the medical world, as it has become clear that a patient’s characteristics have a big influence on the impact of medical treatment. One of these methods is inkjet printing, which has shown potential in creating very low-dosage medicine, even though printing on porous tablets is a novel concept. Clonidine is a medicine which could hugely benefit from lower dosages. Clonidine is a medicine used, among other things, for children with ADHD with or without behavioral problems or tics. The recommended dose of clonidine tablets for children with ADHD is 3-5 μg/day per kg of body weight in 3 doses. The lowest available tablets, however, are of 50 μg. Therefore, small children, with a weight less than 10kg, get too high of a dose of clonidine when this drug is prescribed. Creating porous tablets for inkjet printing could prove to be a good alternative to the existing tablets for lower dosage forms and personalized medicine in general. In this research, we have shown the process of the creation of these porous tablets, with OmyaPharm 500-OG (FCC) powder, a highly porous but poorly flowable powder, as the main compound. This research has shown that powder mixture properties can be improved by adding an automatic granulation step. Also, HPC (hydroxypropyl cellulose) is not a good alternative to MCC (microcrystalline cellulose) as a glidant and binder. This research has helped us to identify the best tablet formulation, API application procedure, and handling of the tablet. Also, the drug release studies were performed. Results showed an adequate release time of less than 15 minutes.